Novo Nordisk A/S (NYSE:NVO) stock has plunged around 41% year to date, as per data from Benzinga Pro.Novo Nordisk’s stock was significantly hit when the company shared headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program, investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.First in May, Novo Nordisk lowered its 2025 sales growth, then again in July, it further trimmed its 2025 guidance. Dur ...